NEW YORK (GenomeWeb) – KineMed and Pronutria Biosciences today announced a collaboration to use KineMed's proteomics platform to evaluate Pronutria's biologics.
Pronutria is developing biologics to restore cellular homeostasis for patients with muscle, neurological, liver, and metabolic disorders and will use the KineMed platform to assess the physiologic effects of its compounds in preclinical and clinical studies.
The KineMed platform uses mass spectrometric analytic techniques to measure the activity of disease-modifying metabolic pathways to detect target engagement, track disease progression, and provide data that are predictive of later-stage clinical trial outcomes, the firm said in a statement. KineMed added that the platform can establish pharmacodynamics, evidence of toxicity, and optimal dose of therapeutics.
Financial and other terms of the agreement were not disclosed.
In April, Emeryville, California-based KineMed signed a deal with Camino Partnership to apply its proteomics platform in drug discovery.